PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
CP-690,550 and Midazolam Drug-Drug Interaction Study
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: midazolam; CP-690,550 + midazolamDrug: CP-690,550 + midazolam; midazolam
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2009-08-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00902460
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00902681
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Study Evaluating Predictors of Response in Patients With Ankylosing Spondylitis
Completed
- Conditions
- Ankylosing Spondylitis
- Interventions
- Other: Treatment switching
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2012-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 132
- Registration Number
- NCT00900796
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease
Phase 2
Terminated
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 526
- Registration Number
- NCT00895895
- Locations
- 🇿🇦
Pfizer Investigational Site, Cape Town, South Africa
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
Phase 4
Completed
- Conditions
- Graft RejectionKidney TransplantRenal TransplantRenal Allograft Recipients
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 254
- Registration Number
- NCT00895583
- Locations
- 🇪🇸
Pfizer Investigational Site, Valencia, Spain
Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects
Phase 1
Completed
- Conditions
- Falciparum Malaria
- Interventions
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2010-06-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00894374
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Study Evaluating Pharmacovigilance Of Refacto AF
Completed
- Conditions
- Hemophilia A
- Interventions
- Drug: ReFacto AF (Moroctocog alfa)
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 101
- Registration Number
- NCT00895037
- Locations
- 🇩🇪
Universitaetsklinikum Duesseldorf, Duesseldorf, Germany
🇩🇪Stiftung Deutsche Klinik fur Diagnostik GmbH, Wiesbaden, Germany
🇩🇪Klinikum Bremen Mitte, Bremen, Germany
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
Phase 4
Completed
- Conditions
- Encephalitis, Tick-Borne
- Interventions
- Biological: FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 179
- Registration Number
- NCT00894686
- Locations
- 🇦🇹
Untergraben 2, Oberösterreich, Austria
🇵🇱Niepubliczny Zakład Opieki Zdrowotnej Ośrodek Zdrowia w Lipsku, Zamosc, Poland
🇩🇪Dr. Ulrich Behre, Baden-Württemberg, Germany
Study Evaluating Impact of the Use of a Computer-based Tool on the Clinical Management of RA Patients
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: Review of clinical records
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2011-07-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 321
- Registration Number
- NCT00895050
A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects
Phase 1
Completed
- Conditions
- Falciparum Malaria
- Interventions
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2010-04-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT00894660
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
© Copyright 2025. All Rights Reserved by MedPath